Table 1.

Demographics and Medication Response

	Total Group	Medication Response
		marked	moderate	nil
PD
subjects (% total PD)	182	125 (68.7%)	41 (22.5%)	16 (8.8%)
% female	29.1%	30.4%	31.7%	12.5%
onset age (yr; mean±SD)	60.8±11.9	58.8±12.5	61.7±13.2	70.6±9.1
disease duration (yr; mean±SD)	16.2±7.7	17.8±9.1	14.6±8.5	10.4±6.0
LED median/mean±SD	650/766±410	700/795±438	600/639±322	825/845±308
LED range	150–2843	150–2843	190–1600	400–1500
dyskinesia	121 (66.5%)	101 (80.8%)	20 (48.8%)	0
wearing off	129 (70.9%)	106 (84.8%)	23 (56.1%)	0
MSA
subjects (% total MSA)	25	4 (16%)	9 (36%)	12 (48%)
% female	56.0%	75.0%	44.4%	58.3%
onset age (yr; mean±SD)	58.6±11.1	49±11.3	60.9±10.8	60.1±9.4
disease duration (yr; mean±SD)	6.9±3.9	8.5±5.3	7.8±4.7	5.7±2.9
LED median/mean±SD	900/922±377	775/849±409	826/964±423	938/915±363
LED range	200–1900	450–1397	600–1900	200–1500
dyskinesia	6 (24%)	3 (75%)	3 (33.3%)	0
wearing off	9 (36%)	4 (100%)	5 (55.6%)	0
PSP
subjects (% total PSP)	18	3 (16.7%)	5 (27.8%)	10 (55.6%)
% female	33.3%	66.7%	40%	40%
onset age (yr; mean±SD)	69.3±7.9	71.3±6.7	76.9±7.6	65.0±5.3
disease duration (yr; mean±SD)	9.1±5.6	17.0±4.9	8.2±6.3	7.2±3.3
LED median/mean±SD	875/924±373	851/934±236	750/810±272	1050/978±455
LED range	300–1630	750–1200	451–1200	300–1630
dyskinesia	5 (27.8%)	1 (33.3%)	4 (80%)	0
wearing off	5 (27.8%)	2 (66.7%)	3 (60%)	0
CBD
subjects (% total CBD)	8	-	1 (12.5%)	7 (87.6%)
% female	25.0%	-	100%	14.3%
onset age (yr; mean±SD)	63.9±9.0	-	66.8	63.5±9.6
disease duration (yr; mean±SD)	6.9±4.6	-	6.9	6.9±4.9
LED median/mean±SD	975/943±336	-	1064	900/926±359
LED range (median)	450–1500	-	1064	450–1500
dyskinesia	1 (12.5%)	-	1	0
wearing off	1 (12.5%)	-	1	0

PD: Parkinson disease

MSA: multiple system atrophy

PSP: progressive supranuclear palsy

CBD: corticobasal degeneration

LED: levodopa equivalent dose (mg)